CC
VKTX icon

Centiva Capital’s Viking Therapeutics VKTX Stock Holding History

Centiva Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$526K – 1617
2025
Q3 		$526K Buy
20,000
+10,000
+100% +$298K 0.01% 624
2025
Q2 		$265K Buy
+10,000
New +$263K ﹤0.01% 1228

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Centiva Capital's VKTX Position: Q1 2026 in Review

Centiva Capital increased its Viking Therapeutics (VKTX) stake by 6.1% in Q1 2026, buying an estimated $24.4K and bringing the position to 13,258 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

Centiva Capital first reported a position in VKTX in Q3 2022 and has held it in 5 quarters since. The position peaked at $3.59M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Centiva Capital held 13,258 shares of Viking Therapeutics worth $431K as of Q1 2026.
  • Centiva Capital bought 758 Viking Therapeutics shares in Q1 2026, an estimated $24.4K.
  • Viking Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #906 holding.
  • Centiva Capital first reported a position in Viking Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • Centiva Capital's Viking Therapeutics position peaked at $3.59M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.